Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | BRAF V600E CD274 pos |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
BRAF V600E CD274 pos | lung adenocarcinoma | predicted - sensitive | Dabrafenib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with CD274 (PD-L1)-positive (IHC = 90% of tumor cells) metastatic lung adenocarcinoma harboring BRAF V600E achieved a partial response to treatment with Tafinlar (dabrafenib) and remained stable with improved performance status for 18 months until disease progression, and subsequently achieved a response to Keytruda (pembrolizumab) treatment (PMID: 29142786). | 29142786 | |
BRAF V600E CD274 pos | lung adenocarcinoma | predicted - sensitive | Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical case study, a patient with CD274 (PD-L1)-positive (IHC = 90% of tumor cells) metastatic lung adenocarcinoma who progressed after an 18-month response to Tafinlar (dabrafenib) treatment based on the presence of BRAF V600E, was then treated with Keytruda (pembrolizumab) for two cycles, and achieved an early response and remained progression-free 7 months after initiating immunotherapy (PMID: 29142786). | 29142786 |